The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019

  • Lowest Price Guaranteed From USD 2,999

  • Published
    April 2019

  • Pages
    242

  • View Count
    2446

Example Insights

Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression and Other)Context Depressive Disorders - Example highlights Depressive Disorders Marketed and Development Pipeline
Depressive Disorders - Distribution by Phase of Development,Type of Therapy,Route of Administration Depressive Disorders-Clinical Trial Analysis Depressive Disorders -Clinical & Commercial Attractiveness Analysis
Depressive Disorders -Partnerships and Collaborations Depressive Disorders -Key Commercialization Strategies  

 

Overview

Depression is a chronic medical condition characterized by a persistent feeling of sadness and lack of interest in external stimuli. It is a commonly diagnosed mental health disorder and is considered among the leading causes of disability across the globe. It has been estimated that over 300 million people (considering all age groups) suffer from depression worldwide. Further, depression and other depressive disorders are projected to be responsible for an economic burden of up to USD 210 billion per year in the US. Despite the high prevalence and significant impact of this disease, less than 50% of affected individuals receive treatment in high-income countries; this figure stands at less than 10% for low-income countries. According to the World Health Organization, barriers to effective care for depression and other depressive disorders, include lack of resources, lack of trained healthcare professionals, inaccurate diagnoses of the condition and the social stigma associated with to mental health disorders.

A number of blockbuster drugs are available to treat depression; these include Prozac and Celexa (approved in 1980s), Paxil and Zoloft (approved in 1990s), and Lexapro and Cymbalta (approved in 2000s). These drugs work by modulating monoamine levels in the brain, a mechanism that has been re-evaluated and improved across the last six decades. Since the 1950s, around 30 branded drugs and more than 150 generic products have been approved by the FDA to treat various forms of depression. Currently, selective serotonin reuptake inhibitors (SSRIs) form the mainstay of treatment options for depression. Despite the availability of generics and other branded drugs, patients have voiced the need for better antidepressants as currently available SSRIs take a long time (few weeks) to demonstrate therapeutic benefit. In addition, around 50% of treated patients do not respond to the first prescribed antidepressant and need to go through months of trial and error-based therapy regimens before an appropriate drug is identified to treat their underlying condition. Further, there are many patients who never respond to any of the available therapeutic strategies, highlighting an urgent need for effective treatment solutions for depression. Several stakeholders in the pharmaceutical industry are currently engaged in efforts to develop various types of interventions and drug / therapy candidates with novel mechanisms of action to treat depression. 
 

Scope of the Report

The “Depressive Disorders Market: Pipeline Review, Developer Landscape and Competitive Insights” report provides an extensive study on the marketed (approved post 2010), clinical and preclinical molecules available / being developed, for the treatment of depressive disorders. Figure 1.1 summarizes the scope of the report and the specific modules that have been covered in detail, in the document.

Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), type of therapy (monotherapy, adjunctive therapy or combination therapy), type of depression (major depressive disorder, bipolar disorder, postpartum depression, treatment-resistant depression and depression (type unknown)), type of drug class (anti-depressant and anti-psychotic), mechanism of action, dosing frequency (twice daily, once daily, twice weekly, once weekly, once in 28 days, twice yearly and once only) and route of administration (oral, nasal and parenteral) of the drugs / therapies being developed for the treatment of depressive disorders.
  • A detailed assessment of discontinued drugs / trials, featuring information on the number of discontinued drug development programs, year of discontinuation, geographical location (of discontinued trial), phase at which the development program was discontinued, mechanism of action of discontinued drug, disease indication (for which the drug was being investigated), reason(s) for discontinuation and information on affiliated developer companies.
  • An analysis of the partnerships that have been established between 2012 and 2019 (till March), covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, clinical trial agreements, and other relevant deals.
  • An analysis of the investments (between 2010 and 2019 (till March)) made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies for different types of depressive disorders. For the purpose of this analysis, we considered the clinical studies registered till February 2019, and analyzed them on the basis of various parameters, such as trial registration year, current trial status, current trial phase, type of depressive disorder, mechanism of action, leading industry and non-industry players with highest number of completed / ongoing trials, regional distribution of clinical trials, and enrolled patient population across different geographies. 
  • An insightful analysis on clinical end-points being evaluated in late-stage ongoing and planned studies, for various types of depressive disorders. For the purpose of this analysis, we considered the phase III clinical studies registered till February 2019, and identified the most important, primary endpoints being evaluated.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population (for the trial in the highest phase of development), route of administration, therapy type and dosing frequency (for quantifying clinical attractiveness), and target patient population, expected launch date and size of developer company (for quantifying commercial attractiveness).
  • An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, post-marketing, and near patent expiry, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products. 
  • A case study on the upcoming digital health solutions for the management / treatment of depression, featuring information on the various product development pathways adopted by companies involved in this segment of the market; it includes brief descriptions of popular digital solutions as well.

The insights presented in this report are backed by a deep understanding of data gathered from secondary sources. The opinions generated over the source of the study, were influenced by inputs from key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified. 
 

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on current and upcoming trends in the depressive disorders market.

Chapter 3 provides a brief introduction to depression, and its associated symptoms. It includes an overview on various types of depressive disorders and features a detailed discussion on the causes and diagnosis of the condition, and the different pharmacological and non-pharmacological interventions that are presently indicated for its treatment. The chapter also includes a discussion on the epidemiology of the disease and highlights the novel approaches for the treatment of depression.

Chapter 4 includes information on over 70 molecules that are currently approved / under development for the treatment of depressive disorders. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), type of therapy (monotherapy or combination therapy), type of depression (major depressive disorder, bipolar disorder, postpartum depression, treatment-resistant depression and depression (type unknown)), type of drug class (anti-depressant and anti-psychotic), mechanism of action, dosing frequency (twice daily, once daily, twice weekly, once weekly, once in 28 days, twice yearly and once only) and route of administration (oral, nasal and parenteral) of the drugs being developed for the treatment of the disease. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength. Additionally, the chapter features a regional landscape of developers engaged in this domain, distributed on the basis of the location of their headquarters.

Chapter 5 features a detailed assessment of 60 discontinued drugs and over 230 discontinued trials, featuring information on the number of discontinued drug development programs, year of discontinuation, geographical location (of discontinued trial), phase at which the development program was discontinued, mechanism of action of discontinued drug, disease indication (for which the drug was being investigated), reason(s) for discontinuation and information on affiliated developer companies.  In addition, the chapter provides a list of over 120 dormant drugs / molecules for which we could not confirm any information regarding the discontinuity on third party sources.

Chapter 6 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed different partnership models, including R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, clinical trial agreements, and other relevant deals, which have been established in this domain, between 2012 and 2019 (till March).

Chapter 7 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, between 2010 and 2019 (till March), highlighting the growing interest of the venture capital community and other strategic investors, within this market.

Chapter 8 is a comprehensive clinical trial analysis of completed, ongoing and planned studies for different types of depressive disorders. For the purpose of this analysis, we considered the clinical studies registered till February 2019, and analyzed them on the basis of various parameters, such as trial registration year, current trial status, current trial phase, type of depressive disorder, mechanism of action, leading industry and non-industry players with highest number of ongoing / completed trials, regional distribution of clinical trials, and enrolled patient population across different geographies.

Chapter 9 features an analysis on the clinical end-points being evaluated in late-stage, ongoing and planned studies, for various types of depressive disorders. For the purpose of this analysis, we considered the phase III clinical studies registered till February 2019, and identified and analyzed the primary endpoints being evaluated.

Chapter 10 features an analysis of the clinical and commercial attractiveness of the drugs designed for the treatment of various types of depressive disorders. In the chapter, each of the drugs / drug candidates were plotted on a 2X2 matrix, with clinical attractiveness (abscissa) and commercial attractiveness (ordinate) as the two axes. The clinical attractiveness of a drug was determined based on the sample size of the associated trial, route of administration, therapy type and dosing frequency. The commercial attractiveness of a drug was determined based on the size of target patient population, expected launch date and company size of the developer company.

Chapter 11 An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, post-marketing, and near patent expiry. It also highlights an in-depth analysis and timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products (for depressive disorders) that were approved post 2010. In addition, it provides a general overview of the drugs considered for studying the strategies in detail.

Chapter 12 is a case study providing an overview on the advancing digital health solutions for the self-management and treatment of depressive disorders. Further, the chapter features information on the various product development pathways adopted by the companies involved in this segment of the market. Moreover, it includes brief descriptions of popular digital solutions.

Chapter 13 summarizes the entire report. The chapter presents a list of key takeaways and our independent opinion on the current market scenario based upon the research and analysis described in the previous chapters.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report. 

Table of Contents

1 PREFACE
1.1. Scope of the Report
1.2 Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION
3.1. An Overview of Depression and Depressive Disorders
3.2. Signs and Symptoms of Depression
3.3. Types of Depression
3.4. Epidemiology of Depression
3.5. Causes of Depression
3.6. Diagnosis of Depression
 
3.7. Current Treatment Paradigms
3.7.1. Pharmacological Treatment
3.7.2. Psychological Treatment
3.7.3. Other Treatments
 
3.8. Innovative Therapeutic Strategies
3.9. Future Perspectives

4 PIPELINE REVIEW: MARKETED AND CLINICAL STAGE DRUGS
4.1. Chapter Overview
4.2. Depressive Disorders: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Depressive Disorder
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Type of Molecules
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Type of Drug and Drug Class
 
4.2.8. Major Depressive Disorder
4.2.8.1. Analysis by Phase of Development
4.2.8.2. Analysis by Route of Administration
4.2.8.3. Analysis by Dosing Frequency
4.2.8.4. Key Players
 
4.2.9. Bipolar Disorder / Bipolar Depression
4.2.9.1. Analysis by Phase of Development
4.2.9.2. Analysis by Route of Administration
4.2.9.3. Analysis by Dosing Frequency
4.2.9.4. Key Players
 
4.2.10. Treatment-Resistant Depression
4.2.10.1. Analysis by Phase of Development
4.2.10.2. Analysis by Route of Administration
4.2.10.3. Analysis by Dosing Frequency
4.2.10.4. Key Players
 
4.2.11. Postpartum Depression and Depression (Type Unknown)
4.2.11.1. Analysis by Phase of Development
4.2.11.2. Analysis by Route of Administration
4.2.11.3. Analysis by Dosing Frequency
4.2.11.4. Key Players
 
4.2.12 Grid Analysis: Distribution by Phase of Development, Type of Depressive Disorder and Type of Drug
 
4.3. Depressive Disorders: List of Drug Developers
4.3.1. Analysis by Year of Establishment of Developers
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location of Developers
4.3.4 Analysis by Type of Depressive Disorder
4.3.5. Key Developers
4.3.6. Grid Analysis: Distribution by Location of Developer, Company Size and Type of Depressive Disorder
 
4.4 Other Novel Ways to Treat Depression
4.4.1. Role of Neurostimulation Devices
4.4.2. Role of Microbiome Therapeutics
 
5 CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS
5.1. Chapter Overview
5.2. Depressive Disorders: Discontinued Drugs
5.2.1. Analysis by Year of Discontinuation
5.2.2. Analysis by Phase of Discontinuation
5.2.3. Analysis by Mechanism of Action
5.2.4. Analysis by Type of Depressive Disorder
5.2.5. Key Players
5.2.6. Analysis by Reason for Discontinuation
 
5.3. Depressive Disorders: Discontinued Clinical Trials
5.3.1. Year-wise Trend of Discontinued Trials
5.3.2. Analysis of Discontinued Clinical Trials by Phase of Development
5.3.3. Analysis of Discontinued Clinical Trials by Sponsor / Collaborator
5.3.4. Analysis of Discontinued Clinical Trials by Geography
5.3.5. Analysis of Discontinued Clinical Trials by Reason of Discontinuation
 
5.4. Concluding Remarks

6 PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Depressive Disorders: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnerships
6.3.2. Analysis by Type of Partnership
6.3.3 Analysis by Type and Year pf Partnership
6.3.4. Analysis by Area of Focus
6.3.5. Analysis by Type of Depressive Disorder
6.3.6. Regional Analysis
6.3.6.1. Local and International Agreements
6.3.6.2. Intercontinental and Intracontinental Agreements
 
6.3.7. Most Active Players: Analysis by Number of Partnerships
6.3.8. Big Pharma Players

7 FUNDING AND INVESTMENT ANALYSIS
7.1. Chapter Overview
7.2. Types of Funding
7.3. Depressive Disorders: Funding and Investment Analysis
7.3.1. Analysis by Number of Instances
7.3.2. Analysis by Amount Invested
7.3.3. High Value Deals: Analysis by Year
7.3.4. Analysis by Type of Funding
7.3.5 Analysis by Number of Funding Instances across Different Therapeutic Areas
7.3.6. Most Active Players
7.3.7. Most Active Investors
7.4. Concluding Remarks

8 CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Depressive Disorders: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Phase
8.3.3. Analysis by Recruitment Status
8.3.4. Analysis by Type of Sponsor / Collaborator
8.3.5. Analysis by Type of Depressive Disorder
8.3.6. Analysis by Type of Drug Class
8.3.7. Most Active Players
8.3.8. Analysis by Number of Clinical Trials and Geography
8.3.9. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
8.3.10. Analysis by Number of Clinical Trials, Type of Depressive Disorder and Geography
8.3.11. Analysis by Number of Clinical Trials, Type of Depressive Disorder, Trial Phase and Geography
8.3.12. Analysis by Number of Clinical Trials, Type of Drug Class and Geography
8.3.13. Analysis by Number of Clinical Trials, Type of Drug Class, Trial Phase and Geography
8.3.14. Analysis by Enrolled Patient Population and Geography
8.3.15. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
8.3.16. Analysis by Enrolled Patient Population, Type of Depressive Disorder and Geography
8.3.17. Analysis by Enrolled Patient Population, Type of Depressive Disorder, Trial Phase and Geography
8.3.18. Analysis by Enrolled Patient Population, Type of Drug Class and Geography
8.3.19. Analysis by Enrolled Patient Population, Type of Drug Class, Trial Phase and Geography
 
8.4. Concluding Remarks
8.4.1. Emerging Molecules to Watch
8.4.2. Most Important Trials to Watch
 
9 CLINICAL TRIAL ENDPOINTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Overview of Most Common Primary Endpoints
9.4. Primary Endpoints Evaluated for Major Depressive Disorder: Comparative Analysis of Late-Stage Drugs
9.5. Primary Endpoints Evaluated for Bipolar Disorder: Comparative Analysis of Late-Stage Drugs
9.6. Primary Endpoints Evaluated for Other Types of Depressive Disorder: Comparative Analysis of Late-Stage Drugs

10 CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.2.1. Assumptions and Key Parameters
 
10.3. Clinical and Commercial Attractiveness Analysis: Depressive Disorders
10.3.1. Clinical and Commercial Attractiveness Analysis: Major Depressive Disorder
10.3.2. Clinical and Commercial Attractiveness Analysis: Bipolar Disorder
10.3.3. Clinical and Commercial Attractiveness Analysis: Other Types of Depressive Disorder

11 KEY COMMERCIALIZATION STRATEGIES
11.1. Chapter Overview
11.2. Successful Drug Launch Strategy: ROOTS Framework
11.3. Successful Drug Launch Strategy: Product Differentiation
11.4. Commercialization Strategies Adopted Based on Development Stage of Product
11.5. Approved Molecules for Treating Depressive Disorders
11.5.1. Abilify Mycite®
11.5.2. Abilify Maintena®
11.5.3. Rexulti®
11.5.4. Vraylar ®
11.5.5. Trintellix®
11.5.6. Fetzima®
11.5.7. Latuda®
11.5.8. Viibryd®
 
11.6. Key Commercialization Strategies Adopted by the Companies Focused on Depressive Disorders
11.6.1. Strategies Adopted Before the Approval of Drug
11.6.1.1. Participation in Global Events
 
11.6.2. Strategies Adopted During the Launch of Drug
11.6.2.1. Collaboration with Internal Stakeholders and Pharmaceutical Firms
11.6.2.2. Awareness through Product Websites
11.6.2.3. Direct to Consumer (DTC) Advertisements
 
11.6.3. Strategies Adopted Post Drug Launch / Near Patent Expiry of Drug
11.6.3.1. Approval of Drug in Multiple Geographies
11.6.3.2. Approval of Drug for Multiple Indications
 
11.7. Concluding Remarks

12 DIGITAL THERAPEUTICS FOR DEPRESSIVE DISORDERS
12.1. Chapter Overview
12.2. An Overview on Digital Therapeutics
12.3. Development and Commercialization Pathway for Digital Therapeutics
12.3.1. Discovery and Preclinical Research
12.3.2. Clinical Trials and Validation
12.3.3. Engaging Insurance Providers / Payers
12.3.4. Distribution and Marketing
 
12.4. Digital Therapeutics for Depressive Disorders
12.4.1. Standalone Software Applications
12.4.2. Personal Coaching
12.4.3. AI Support
12.4.4. Gaming Solutions
12.5 Concluding Remarks

13 CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways

14 APPENDIX 1: TABULATED DATA

15 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 1.1 Depressive Disorders: Scope and Competitive Insights
Figure 3.1 Depression: Key Facts
Figure 3.2 Depression: Common Signs and Symptoms
Figure 3.3 Prevalence of Depression in Major Geographical Regions
Figure 3.4 Prevalence of Depression in Major Geographical Regions by Gender
Figure 3.5 Global Prevalence of Depression: Distribution by Gender and Age Groups
Figure 3.6 Prevalence of Various Types of Depression in the US
Figure 3.7 Causes of Depression
Figure 4.1 Depressive Disorders: Distribution by Phase of Development
Figure 4.2 Depressive Disorders: Distribution by Type of Depressive Disorder
Figure 4.3 Depressive Disorders: Distribution by Type of Depressive Disorder and Phase of Development
Figure 4.4 Depressive Disorders: Distribution by Type of Therapy
Figure 4.5 Depressive Disorders: Distribution by Type of Molecule
Figure 4.6 Depressive Disorders: Distribution by Route of Administration
Figure 4.7 Depressive Disorders: Distribution by Dosing Frequency
Figure 4.8 Depressive Disorders: Distribution by Type of Drug and Drug Class
Figure 4.9 Major Depressive Disorder: Distribution by Phase of Development
Figure 4.10 Major Depressive Disorder: Distribution by Route of Administration
Figure 4.11 Major Depressive Disorder: Distribution by Dosing Frequency
Figure 4.12 Major Depressive Disorder: Key Players
Figure 4.13 Bipolar Disorder / Bipolar Depression: Distribution by Phase of Development
Figure 4.14 Bipolar Disorder / Bipolar Depression: Distribution by Route of Administration
Figure 4.15 Bipolar Disorder / Bipolar Depression: Distribution by Dosing Frequency
Figure 4.16 Bipolar Disorder / Bipolar Depression: Key Players
Figure 4.17 Treatment-Resistant Depression: Distribution by Phase of Development
Figure 4.18 Treatment-Resistant Depression: Distribution by Route of Administration
Figure 4.19 Treatment-Resistant Depression: Distribution by Dosing Frequency
Figure 4.20 Treatment-Resistant Depression: Key Players
Figure 4.21 Postpartum Depression and Depression (Type Unknown): Distribution by Phase of Development
Figure 4.22 Postpartum Depression and Depression (Type Unknown): Distribution by Route of Administration
Figure 4.23 Postpartum Depression and Depression (Type Unknown): Distribution by Dosing Frequency
Figure 4.24 Grid Analysis: Distribution of Pipeline Therapies by Phase of Development, Type of Depressive Disorder and Type of Drug
Figure 4.25 Depressive Disorders: Distribution by Year of Establishment of Developer
Figure 4.26 Depressive Disorders: Distribution by Size of Developer (Employee Count)
Figure 4.27 Depressive Disorders: Distribution of Developers by Geographical Location (Continents)
Figure 4.28 Depressive Disorders: Distribution of Developers by Geographical Location (Countries)
Figure 4.29 Depressive Disorders: Distribution of Developers by Type of Depressive Disorder
Figure 4.30 Depressive Disorders: Leading Players
Figure 4.31 Grid Analysis: Distribution by Location of Developer, Company Size (Employee Count) and Type of Depressive Disorder
Figure 5.1 Failure Analysis: Cumulative Distribution of Drugs by Year of Discontinuation
Figure 5.2 Failure Analysis: Distribution by Phase of Discontinuation
Figure 5.3 Failure Analysis: Distribution by Mechanism of Action
Figure 5.4 Failure Analysis: Distribution by Type of Depressive Disorder
Figure 5.5 Failure Analysis: Key Players
Figure 5.6 Failure Analysis: Distribution by Reason of Discontinuation
Figure 5.7 Failure Analysis: Relative Distribution by Reasons of Discontinuation and Phase of Development
Figure 5.8 Failure Analysis: Year-wise Distribution of Discontinued Trials
Figure 5.9 Failure Analysis: Distribution of Discontinued Trials by Trial Phase and Average Time to Discontinuation
Figure 5.10 Failure Analysis: Distribution of Discontinued Trials by Type of Sponsor / Collaborator
Figure 5.11 Failure Analysis: Distribution of Discontinued Trials by Geography
Figure 5.12 Failure Analysis: Distribution of Discontinued Trials by Year of Discontinuation and Geography
Figure 5.13 Failure Analysis: Distribution of Discontinued Trials by Reason of Discontinuation
Figure 5.14 Bubble Analysis: Distribution of Discontinued Trials by Year of Discontinuation, Reason of Discontinuation and Phase of Development
Figure 6.1 Partnerships and Collaborations: Cumulative Trend of Activity, by Year, 2012-2019
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Area of Focus
Figure 6.5 Partnerships and Collaborations: Distribution by Type of Depressive Disorder
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 6.8 Partnerships and Collaborations: Most Active Players
Figure 6.9 Partnerships and Collaborations: Activity of Big Pharmaceutical Companies
Figure 7.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Developer, 2010-2019
Figure 7.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2010-2019
Figure 7.3 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2010-2019 (USD Million)
Figure 7.4 Funding and Investment Analysis: Average Amount Invested per Year (USD Million), 2010-2019
Figure 7.5 Funding and Investment Analysis: High Value Deals (USD Million), 2010-2019
Figure 7.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2010-2019
Figure 7.7 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2010-2019 (USD Million)
Figure 7.8 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2010-2014 and Post 2014
Figure 7.9 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2010-2014 and Post 2014 (USD Million)
Figure 7.10 Funding and Investment Analysis: Distribution of Funding Instances across Major Therapeutic Areas
Figure 7.11 Funding and Investment Analysis: Most Active Players
Figure 7.12 Funding and Investment Analysis: Key Investors
Figure 7.11 Funding and Investment Summary, 2010-2019 (USD Million)
Figure 8.1 Clinical Trial Analysis: Cumulative Distribution of Clinical Trials by Start Year, 2001-2019
Figure 8.2 Clinical Trial Analysis: Distribution of Clinical Trials by Study Start Year and Geography, 2001-2019
Figure 8.3 Clinical Trial Analysis: Distribution of Patients Enrolled by Study Start Year, 2001-2019
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Recruitment Status
Figure 8.8 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Trial Registration Year
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Drug Class
Figure 8.10 Clinical Trials Analysis: Most Active Industry and Non-Industry Players in Terms of Number of Trials Conducted
Figure 8.11 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.12 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Recruitment Status and Geography
Figure 8.13 Clinical Trial Analysis: Distribution of Clinical Trials by Type of Depressive Disorder and Geography
Figure 8.14 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Type of Depressive Disorder and Geography
Figure 8.15 Clinical Trial Analysis: Distribution of Clinical Trials by Type of Drug Class and Geography
Figure 8.16 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Phase, Mechanism of Action and Geography
Figure 8.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 8.18 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Recruitment Status and Geography
Figure 8.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Type of Depressive Disorder and Geography
Figure 8.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Type of Depressive Disorder and Geography
Figure 8.21 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Type of Drug Class and Geography
Figure 8.22 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase, Mechanism of Action and Geography
Figure 10.1 Clinical Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Depressive Disorders
Figure 10.2 Clinical and Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Major Depressive Disorder
Figure 10.3 Clinical and Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Bipolar Disorder / Bipolar Depression
Figure 10.4 Clinical and Commercial Attractiveness Analysis: Late Stage Molecules Under Investigation for Treating Other Depressive Disorders
Figure 11.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 11.2 Successful Drug Launch Strategy: Product Differentiation
Figure 11.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 11.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Depressive Disorders
Figure 11.5 Participation in Global Events: Historical Timeline
Figure 11.6 Approved Drugs for Depressive Disorders: Promotional Activities through Product Websites
Figure 11.7 Approval of Drugs in Multiple Geographies: Historical Timeline
Figure 11.8 Approval of Drugs for Multiple Indications: Historical Timeline
Figure 12.1 Prescription Digital Therapeutics: Process Map
Figure 12.2 Digital Therapeutics: Google Trends (2008-2018)

List of Tables

Table 3.1 List of FDA Approved Antidepressants
Table 4.1 Depressive Disorders: Marketed and Development Pipeline
Table 4.2 Depressive Disorders: Information on Special Designations
Table 4.3 Depressive Disorders: Information on Site of Drug Administration
Table 4.4 Depressive Disorders: Information on Drug Type, Drug Class and Mechanism of Action
Table 4.5 Depressive Disorders: Developer Overview
Table 4.6 List of Neurostimulation Devices (Invasive) for Depression
Table 4.7 List of Neurostimulation Devices (Non-Invasive) for Depression
Table 5.1 Depressive Disorders: Pipeline of Discontinued Drugs
Table 5.2 Depressive Disorders: List of Discontinued Clinical Trials
Table 5.3 Depressive Disorders: List of Discontinued Drugs (Unvalidated)
Table 6.1 Depressive Disorders: Partnerships and Collaborations, 2012-2019
Table 7.1 Depressive Disorders: Funding and Investments, 2010-2019
Table 7.2 Funding and Investment Analysis: Summary of Investments
Table 8.1 Clinical Trial Analysis: Emerging Molecules to Watch
Table 8.2 Clinical Trial Analysis: Most Important Trials to Watch
Table 9.1 Clinical Trial Endpoint Analysis: List of Drugs
Table 9.2 Clinical Endpoint Analysis: Key Primary Endpoints Evaluated for Major Depressive Disorder
Table 9.3 Clinical Endpoint Analysis: Key Primary Endpoints Evaluated for Bipolar Disorder / Bipolar Depression
Table 9.4 Clinical Trial Endpoint Analysis: Key Primary Endpoints Evaluated for Other Depressive Disorders
Table 11.1 Drug Snapshot: Abilify Mycite®
Table 11.2 Drug Snapshot: Abilify Maintena®
Table 11.3 Drug Snapshot: Rexulti®
Table 11.4 Drug Snapshot: Vraylar®
Table 11.5 Drug Snapshot: Trintellix®
Table 11.6 Drug Snapshot: Fetzima®
Table 11.7 Drug Snapshot: Latuda®
Table 11.8 Drug Snapshot: Viibryd®
Table 11.9 Patient Support Services on Product Websites of Drugs for Depressive Disorders: Comparative Analysis
Table 11.10 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 12.1 Digital Therapeutics for Depressive Disorders: List of Solutions
Table 13.1 Depressive Disorders: Summary of Competitive Insights
Table 14.1 Global Prevalence of Depression: Distribution by Gender and Age Groups
Table 14.2 Depressive Disorders: Distribution by Phase of Development
Table 14.3 Depressive Disorders: Distribution by Type of Depressive Disorder
Table 14.4 Depressive Disorders: Distribution by Type of Depressive Disorder and Phase of Development
Table 14.5 Depressive Disorders: Distribution by Type of Therapy
Table 14.6 Depressive Disorders: Distribution by Type of Molecules
Table 14.7 Depressive Disorders: Distribution by Route of Administration
Table 14.8 Depressive Disorders: Distribution by Dosing Frequency
Table 14.9 Depressive Disorders: Distribution by Type Drug and Drug Class
Table 14.10 Major Depressive Disorder: Distribution by Phase of Development
Table 14.11 Major Depressive Disorder: Distribution by Route of Administration
Table 14.12 Major Depressive Disorder: Distribution by Dosing Frequency
Table 14.13 Major Depressive Disorder: Key Players
Table 14.14 Bipolar Disorder / Bipolar Depression: Distribution by Phase of Development
Table 14.15 Bipolar Disorder / Bipolar Depression: Distribution by Route of Administration
Table 14.16 Bipolar Disorder / Bipolar Depression: Distribution by Dosing Frequency
Table 14.17 Bipolar Disorder / Bipolar Depression: Key Players
Table 14.18 Treatment-Resistant Depression: Distribution by Phase of Development
Table 14.19 Treatment-Resistant Depression: Distribution by Route of Administration
Table 14.20 Treatment-Resistant Depression: Distribution by Dosing Frequency
Table 14.21 Postpartum Depression and Depression (Type Unknown): Distribution by Phase of Development
Table 14.22 Postpartum Depression and Depression (Type Unknown): Distribution by Route of Administration
Table 14.23 Postpartum Depression and Depression (Type Unknown): Distribution by Dosing Frequency
Table 14.24 Depressive Disorders: Distribution by Year of Establishment of Developer
Table 14.25 Depressive Disorders: Distribution by Company Size (Employee Count)
Table 14.26 Depressive Disorders: Distribution of Developers by Geographical Location (Continents)
Table 14.27 Depressive Disorders: Distribution of Developers by Geographical Location (Countries)
Table 14.28 Depressive Disorders: Distribution of Developers by Type of Depressive Disorder
Table 14.29 Depressive Disorders: Key Players
Table 14.30 Failure Analysis: Cumulative Distribution of Drugs by Year of Discontinuation
Table 14.31 Failure Analysis: Distribution by Phase of Discontinuation
Table 14.32 Failure Analysis: Distribution by Mechanism of Action
Table 14.33 Failure Analysis: Distribution by Type of Depressive Disorder
Table 14.34 Failure Analysis: Key Players
Table 14.35 Failure Analysis: Distribution by Reason of Discontinuation
Table 14.36 Failure Analysis: Relative Distribution by Reasons of Discontinuation and Phase of Development
Table 14.37 Failure Analysis: Distribution of Discontinued Trials by Trial Phase and Average Time to Discontinuation
Table 14.38 Failure Analysis: Distribution of Discontinued Trials by Type of Sponsor / Collaborator
Table 14.39 Failure Analysis: Distribution of Discontinued Trials by Reason of Discontinuation
Table 14.40 Partnerships and Collaborations: Cumulative Trend of Activity, by Year, 2012-2019
Table 14.41 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.42 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Table 14.43 Partnerships and Collaborations: Distribution by Area of Focus
Table 14.44 Partnerships and Collaborations: Distribution by Type of Depressive Disorder
Table 14.45 Partnerships and Collaborations: Regional Distribution
Table 14.46 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 14.47 Partnerships and Collaborations: Most Active Players
Table 14.48 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2010-2019
Table 14.49 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2010-2019 (USD Million)
Table 14.50 Funding and Investments: Average Amount Invested per Year (USD Million), 2010-2019
Table 14.51 Funding and Investment Analysis: High Value Deals (USD Million), 2010-2019
Table 14.52 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2010-2019
Table 14.53 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2010-2019 (USD Million)
Table 14.54 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2010-2014 and Post 2014
Table 14.55 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2010-2014 and Post 2014 (USD Million)
Table 14.56 Funding and Investment Analysis: Distribution of Funding Instances across Major Therapeutic Areas
Table 14.57 Funding and Investment Analysis: Most Active Players
Table 14.58 Clinical Trial Analysis: Cumulative Distribution of Clinical Trials by Start Year, 2001-2019
Table 14.59 Clinical Trial Analysis: Distribution of Clinical Trials by Study Start Year and Geography, 2001-2019
Table 14.60 Clinical Trial Analysis: Distribution of Patients Enrolled by Study Start Year, 2001-2019
Table 14.61 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 14.62 Clinical Trial Analysis: Distribution by Trial Status
Table 14.63 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.64 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Recruiting Status
Table 14.65 Clinical Trial Analysis: Distribution by Type of Depressive Disorder and Trial Registration Year
Table 14.66 Clinical Trial Analysis: Distribution by Type of Drug Class
Table 14.67 Clinical Trials Analysis: Most Active Industry and Non-Industry Players in Terms of Number of Trials Conducted

List of Companies

The following companies and organizations have been mentioned in the report.

  1. 23andMe
  2. 4D Pharma
  3. Abbott Laboratories
  4. AbbVie
  5. AbleTo
  6. ACADIA Pharmaceuticals
  7. Ad Scientiam
  8. Addex Therapeutics
  9. Advocate Health Care
  10. Aescap Venture
  11. Affectis Pharmaceuticals
  12. Akili Interactive
  13. Aleva Neurotherapeutics
  14. Alexandria Real Estate Equities
  15. Alkermes
  16. Allergan
  17. Altitude Life Science Ventures
  18. American BriVision
  19. Amorsa Therapeutics
  20. Anavex Life Sciences
  21. Angelini
  22. Apeiron Investment Group
  23. Apple Tree Partners
  24. Aptinyx
  25. ARCH Venture Partners
  26. Armistice Capital
  27. Aspire Capital Fund
  28. AstraZeneca
  29. ATAI Life Sciences
  30. Atlas Venture
  31. Axial Biotherapeutics
  32. Axsome Therapeutics
  33. Bail Capital
  34. Bain Capital Life Sciences
  35. Bayer Schering Pharma
  36. Bayern Kapital
  37. Baylor College of Medicine
  38. BioLite
  39. Biomatics Capital
  40. BlackThorn Therapeutics
  41. Blue Turtle Bio Technologies
  42. Boehringer Ingelheim
  43. Brace Pharma Capital
  44. BrainCells
  45. BrainsWay
  46. Bristol-Myers-Squibb
  47. Canaan Partners
  48. Cellix Bio
  49. Celon Pharma
  50. CeNeRx BioPharma
  51. CepTor
  52. Cerbomed
  53. Cerecor
  54. Cingulate Therapeutics
  55. Click Therapeutics
  56. Cognition Kit
  57. COMPASS Pathways
  58. Corcept Therapeutics
  59. Cormorant Asset Management
  60. DAFNA Capital Management
  61. Dart NeuroScience
  62. Domain Associates
  63. Eli Lilly
  64. EMBL Ventures
  65. EPIX Pharmaceuticals
  66. e-therapeutics
  67. Euthymics Bioscience
  68. Evotec
  69. Fabre-Kramer Pharmaceuticals
  70. Federated Investors
  71. Fisher Wallace Laboratories
  72. Flow Neuroscience
  73. Foundation Medical Partners
  74. FUJIFILM Cellular Dynamics
  75. GAIA
  76. Gedeon Richter
  77. GlaxoSmithKline
  78. GNT Pharma
  79. Google Ventures
  80. GrowthWorks
  81. Hercules Capital
  82. Highland Capital Partners
  83. Holmusk
  84. Holobiome
  85. HOST Therabiomics
  86. IBM Watson Health
  87. Ieso Digital Health
  88. Index Ventures
  89. Intra-Cellular Therapies
  90. INVENT Pharmaceuticals
  91. Inventages
  92. ITF Pharma
  93. Janssen Pharmaceutica
  94. Jiangxi Synergy Pharmaceutical
  95. Johnson & Johnson Innovation
  96. Joyable
  97. Kallyope
  98. Karolinska Institutet
  99. KfW
  100. King’s College London
  101. Lantern Health
  102. Leerink Partners
  103. Lincoln Park Capital
  104. LivaNova
  105. Livongo Health
  106. Luc Therapeutics
  107. Lundbeck
  108. Luye Pharma Group
  109. MAG & More
  110. Magellan Health
  111. Magstim
  112. MagVenture
  113. Marinus Pharmaceuticals
  114. MaRS Innovation
  115. Merck
  116. Mercury Fund
  117. Meru Health
  118. Milken Institute
  119. Mindstrong Health
  120. Minerva Neurosciences
  121. Mission Pharmacal
  122. Morrison & Foerster
  123. MPM Capital
  124. M's Science
  125. MSI Methylation Sciences
  126. Mylan
  127. myStrength
  128. National Institute of Mental Health
  129. National Institute of Neurological Disorders and Stroke
  130. Naurex
  131. Navitor Pharmaceuticals
  132. Neosync
  133. NeRRe Therapeutics
  134. Neuralstem
  135. neuroCare
  136. NeuroNascent
  137. Neuronetics
  138. NeuroQore
  139. NeuroRx Pharma
  140. NeuroSearch
  141. NeuroSigma
  142. New Enterprise Associates
  143. Nexstim
  144. Novartis
  145. Omada Health
  146. Ono Pharmaceutical
  147. Ontario Brain Institute
  148. Organon (acquired by Scheing-Plough)
  149. Orion
  150. Otsuka Pharmaceutical
  151. Pear Therapeutics
  152. Perceptive Advisors
  153. Pfizer
  154. Pherin Pharmaceuticals
  155. Philips
  156. Pierre Fabre
  157. Platinum Long Term Growth VII
  158. Polaris Partners
  159. Principia SGR
  160. Proteus Digital Health
  161. Pura Vida Investments
  162. Quark Venture
  163. Reckitt Benckiser
  164. Relmada Therapeutics
  165. RespireRx Pharmaceuticals (formerly Cortex Pharmaceuticals)
  166. Revaax Pharmaceuticals
  167. Reviva Pharmaceuticals
  168. Rexahn Pharmaceuticals
  169. Roche
  170. RusnanoMedInvest
  171. SAGE Therapeutics
  172. Salk Institute
  173. Sanford Burnham Prebys Medical Discovery Institute
  174. Sanofi
  175. Schering-Plough
  176. Schrödinger
  177. Servier
  178. Shanghai Medicilon
  179. Shenox Pharmaceuticals
  180. Shionogi
  181. Shire (acquired by Takeda Pharmaceutical)
  182. Silicon Valley Bank
  183. Sio Capital Management
  184. SK Biopharmaceuticals
  185. SK C & C
  186. Sofinnova Ventures
  187. Solvay
  188. Soterix Medical
  189. Sound Pharmaceuticals
  190. SR One
  191. Subversive Capital
  192. Sumitomo Dainippon Pharma
  193. Sun Pharma Advanced Research Company
  194. Sunovion Pharmaceuticals
  195. Suven Life Sciences
  196. Synergia Medical
  197. Takeda Pharmaceutical
  198. Tal Medical
  199. Targacept
  200. The Johns Hopkins University School of Medicine
  201. The Longevity Fund
  202. Third Rock Ventures
  203. Tianjin Pharmaceutical Holdings
  204. Toyota Tsusho
  205. University of Michigan
  206. University of Oxford
  207. University of Toronto
  208. VANDA Pharmaceuticals
  209. Venrock
  210. VistaGen Therapeutics
  211. Wellcome Trust
  212. WestRiver Group
  213. Worldwide Clinical Trials
  214. Yungjin Pharmaceuticals

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,999

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com